nimesulide

ApprovedSmall molecule

Boehringer Ingelheim

nimesulide is one of 78 small molecule programs targeting Respiratory tract infection. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Respiratory Tract InfectionActive, not recruiting

Breast CancerActive, not recruiting

PharyngitisActive, not recruiting

Respiratory Tract InfectionApproved

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

PharyngitisApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

nimesulide

Boehringer Ingelheim

Approved

1 2

Megace

Bristol-Myers Squibb

Preclinical

4 3

DATROWAY

Daiichi Sankyo

Preclinical

4 4

Zolymbus

AbbVie

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Acupan

YYonsei University

Preclinical

1 7

Chantix

PPrism Pharmaceuticals

Preclinical

1 8

Paracetamol

GSK

Preclinical

1 9

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 10

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

A Prevention Trial in Subjects at High Risk for Breast Cancer

Completed·EEuropean Institute of Oncology·Phase 2·NCT01500577·150 enrolled

Pharyngitis1 trial

Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02229747·128 enrolled

Effectiveness1 trial

Comparative Analysis of the Effectiveness of the Use of Nimesulide and CBD Oil in Patients With Pain in the Preauricular Region Due to the Pain-dysfunctional Syndrome of the Temporomandibular Joint.

Unknown status·PPomeranian Medical University Szczecin·Phase 2·NCT04609748·30 enrolled

Respiratory tract infection1 trial

Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection

Withdrawn· Novartis logo

Novartis·Phase 4·NCT01257126

Unspecified1 trial

Bioequivalence Study of Nimesulide 100 mg Tablets

Completed· GSK logo

GSK·Phase 1·NCT01745614·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for nimesulide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nimesulide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nimesulide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Boehringer Ingelheim

nimesulide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

Pharyngitis1 trial

Effectiveness1 trial

Respiratory tract infection1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News